Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced that it has received marketing approval in Kyrgyzstan for its enoxaparin products, available in 0.4mL and 0.6mL dosages. Enoxaparin, originally developed by Sanofi, is recognized for its significant efficacy in preventing venous thromboembolic diseases following orthopedic or general surgery and in managing cardiovascular conditions such as deep vein thrombosis and unstable angina pectoris.
Changshan Bio’s generic enoxaparin is now approved for use in Kyrgyzstan to prevent venous thromboembolic diseases, particularly thrombosis associated with orthopedic or general surgery. It is also indicated for the treatment of established deep vein thrombosis, with or without pulmonary embolism, in patients with mild clinical symptoms not requiring surgical intervention or thrombolytic therapy. Additionally, it is used in combination with aspirin for the treatment of unstable angina and non-Q-wave myocardial infarction, as well as for preventing thrombus formation during extracorporeal circulation in hemodialysis.- Flcube.com
